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Although first suggested at the turn of the 20th century, there
is a renewed interest in the infectious theory of atherosclerosis.
Studies done in many laboratories around the world over the past
several years have shown an association between markers of
inflammation and coronary atherosclerosis with an exacerbation
of the inflammatory process during acute myocardial ischemia,
particularly in the early stages of reperfusion. It is also being
recognized that the traditional risk factors, such as smoking,
dyslipidemia, hypertension and diabetes mellitus, do not explain
the presence of coronary atherosclerosis in a large proportion of
patients. We believe that in certain genetically susceptible people,
infection with very common organisms, such as Chlamydia pneu-
moniae or cytomegalovirus, may lead to a localized infection and a
chronic inflammatory reaction. Persistence of infection may relate
to the degree of inflammation and severity of atherosclerosis.
Early trials with appropriate antibiotic agents in some patients
with a recent history of acute myocardial infarction have led to
very salutary results. If patients with an infectious basis of
atherosclerosis can be identified, a therapy directed at eradication
of the offending organism may be appropriate.
(J Am Coll Cardiol 1998;31:1217–25)
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Atherosclerosis, with its major manifestation coronary artery
disease (CAD), is the major cause of morbidity and mortality
in the West. Although there has been a marked decline in
death from CAD, especially in the United States and to a lesser
extent in Europe, during the past 20 years, the prevalence of
CAD-related morbidity and mortality in Asia, with almost
one-half of the world population, is steadily increasing (1,2).
Epidemiologic studies have identified several risk factors, such
as smoking, diabetes mellitus, hypertension and dyslipidemia,
in the pathogenesis of atherosclerosis. The decline in CAD-
related mortality in the West has been ascribed to control of
these traditional risk factors and utilization of innovative
pharmacologic and coronary interventional therapies (3–5).
Several new risk factors, such as homocysteinemia, elevated
plasma levels of lipoprotein(a) [Lp(a)], excessive iron load in
the body, an imbalance between oxidant and antioxidant
species and hypercoagulability, are being described in athero-
sclerosis (6–11). Several genetic markers of atherosclerosis
and CAD, such as angiotensin-converting enzyme polymor-
phism and human leukocyte antigen (HLA)-DR class II geno-
types, have also been identified (12–15).
Experimental and clinical studies, based on the markers of
inflammation and inflammatory mediators in plasma, as well as
in tissue samples obtained from atherosclerotic tissues, have
provided ample evidence for the presence of ongoing inflam-
mation in atherosclerosis (16–22). This has led to the sugges-
tion that CAD may be an inflammatory, autoimmune disease.
The precise stimulus for inflammation continues to elude the
investigators; however, new data suggest that bacterial, para-
sitic or viral infection may initiate the inflammatory process (23).
Another major focus of current interest in the pathophysi-
ology of atherosclerosis and its clinical manifestations is the
role of the powerful vasodilator species nitric oxide and
alterations in its synthesis, release and activity (24).
In this report, we review our current understanding of the
interactive role of different factors in the pathogenesis of
CAD, with special emphasis on infection leading to inflamma-
tion and alterations in several metabolic abnormalities identi-
fied in patients with CAD. If the hypotheses proposed herein
are proved, new preventive and therapeutic approaches may
then be designed.
Inflammation and CAD
Association of inflammation with acute myocardial isch-
emia has been known for almost 60 years (25). Infiltration of
inflammatory cells in and around the infarcted regions soon
after the onset of the ischemic process has been thought to
represent part of the healing process. However, it has become
amply evident that infiltration of inflammatory cells contrib-
utes to infarct extension and expansion and inflammation is a
key component of myocardial ischemic injury (26).
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Animal studies. Work done in the animal laboratory has
demonstrated the accumulation of leukocytes and their subse-
quent activation in the blood vessels and myocardium soon
after reperfusion. The leukocyte infiltration plateaus at about
4 to 10 h (26). Leukocyte-mediated injury occurs as a result of
physical obstruction of the microvasculature in the reperfused
tissues (18,19) and release of oxygen-free radicals, proteolytic
enzymes, especially elastase (27), and arachidonic acid metab-
olites (28). The initial infiltration of leukocytes occurs in
response to chemotactic stimuli, principally complement (29).
Work done in several laboratories has defined the steps
leading to leukocyte attachment to the activated endothelial
cells and infiltration into the subendothelial vascular layers,
and thereafter into the reperfused myocardial tissues. This
work includes identification and expression of various adhesion
molecules on activated endothelial cells (e.g., P-selectin, inter-
cellular adhesion molecules) and their counterligands on
leukocytes (26). Similarly, release of several mediators of
inflammation, mainly cytokines (e.g., tumor necrosis factor
[TNF-alpha] and interleukins [ILs]), has been described during
the early stages of myocardial ischemia (30). There is also
evidence of infiltration of reperfused tissues with monocytes
and T lymphocytes. Activation of these cells results in release
of TNF-alpha, macrophage colony-stimulating factor, macro-
phage chemoattractant protein-1 and other activators of coag-
ulation cascade (31). Collectively, these mediators may facili-
tate propagation of in situ thrombosis and atherosclerosis, and
hence the ischemic process.
These data have led to the concept that ischemia begets
more ischemia. Identification of various steps involved in
infiltration of ischemic tissues by leukocytes, particularly at the
border zone between infarcted and noninfarcted myocardium,
has been the basis for use of novel strategies focused on
limitation of tissue injury. The therapies tested thus far in the
animal models of myocardial ischemia have included interfer-
ence with the generation of leukocyte chemotactic factors,
such as complement depletion with cobra venom toxin (32), or
with blockade of adhesion molecules and their counterligands
on leukocytes (33,34). Recent studies have also included use of
specific inhibitors of different cytokines (35). Other strategies
have been designed to deplete neutrophils with antineutrophil
antibodies (36), chemicals (37) and neutrophil filters (38) or to
inhibit neutrophil function with prostacyclin analogs (39),
lipoxygenase inhibitors (37) or mixed cyclooxygenase and
lipoxygenase inhibitors (40). The role of oxygen free radicals
and elastase with specific inhibitors (41,42) has also been
examined. All these strategies have demonstrated reduction in
infarct size, albeit to a varying degree, in animal models of
myocardial ischemic injury.
Other studies designed to limit inflammation in atherogen-
esis in experimental models are currently in progress, although
the results thus far have not shown a uniform benefit of this
strategy.
In animal models of atherosclerosis induced by a high
cholesterol diet, the first cells to appear on the surface of
endothelium are monocytes, which soon migrate to the suben-
dothelial layers, engulf oxidized cholesterol and transform into
macrophages (16). The lipid core of the atherosclerotic region
is characterized by the presence of T lymphocytes, a hallmark
of the immune process. The activated T lymphocytes inhibit
collagen synthesis by secretion of interferon-gamma (IFN-
gamma) and thus interfere with the maintenance and repair of
the collagenous framework of the plaque’s fibrous cap. IFN-
gamma secretion facilitates formation, retention and activation
of macrophages, which can breakdown both collagen and
elastin. Release of cytokines stimulates neovascularization, in
situ thrombosis and loss of endothelium’s ability to generate
nitric oxide (43). Rupture of neovascular channels within the
plaque leads to hemorrhage and thrombosis. These processes
collectively have been attributed to the evolution of unstable
coronary syndromes (31).
Evidence of inflammation in patients with CAD. Inflam-
mation, as evident by a high blood cell count and high
erythrocyte sedimentation rate, has been thought to reflect the
body’s response to tissue injury in patients with acute myocar-
dial infarction. Work from several laboratories in recent years
suggests that inflammation is part and parcel of the syndrome
of ischemia-reperfusion injury and that the degree of inflam-
mation correlates with the severity and outcome of acute
myocardial ischemia.
Studies by Friedman et al. (44) in 1974 and by Kostis et al.
(17) and Lowe et al. (45) in the early 1980s suggested that total
leukocyte count correlates with the extent and severity of
coronary atherosclerosis and initial leukocyte count during
acute myocardial infarction independently predicts the fre-
quency of early ventricular fibrillation. Studies from our insti-
tution showed an enhanced chemotactic response of neutro-
phils and an increased leukotriene B4 generation in patients
with stable angina. Patients with unstable angina and acute
myocardial infarction showed increased chemotaxis and mor-
phologic evidence of degranulation and increased levels of
neutrophil elastase activity in plasma (46,47). De Servi et al.
(48) subsequently confirmed the increased neutrophil activity
in patients with exercise-induced angina. They suggested that
“priming” of neutrophils in stable angina may enhance platelet
aggregation and predispose patients to the development of
acute coronary syndromes. These authors also documented
release of neutrophil elastase during coronary angioplasty in
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patients with stable angina (49). Neri Serneri et al. (50) in
elegant studies in patients with a variety of CAD patients
showed that peripheral blood lymphocytes from patients with
unstable angina are also activated and these activated cells
induce expression of procoagulant activity of monocytes.
Mazonne et al. (51) described an increased expression of
neutrophil and monocyte adhesion molecules in unstable
CAD. CD11b/CD18 expression was higher in the coronary
sinus blood than in the aortic blood, indicating intracoronary
expression of adhesion molecules in unstable coronary syn-
dromes. Similarly, Rab et al. (52) measured monocyte-
macrophage Leu-M3
1 marker and HLA-DR surface antigens
in circulating blood and found these to be increased in patients
with unstable angina. We (53) measured circulating levels of
intercellular adhesion molecule-1 released from activated en-
dothelial cells and L-selectin shed into the blood from acti-
vated leukocytes in patients with a variety of CAD syndromes
and found elevated levels of circulating intercellular adhesion
molecule-1 in all patients with CAD compared with control
subjects, with the highest levels in patients with acute ischemic
syndromes. In contrast, plasma L-selectin levels were dimin-
ished in CAD patients. Stimulation of leukocytes in vitro was
demonstrated to be associated with downregulation of
L-selectin expression measured by flow cytometry, suggesting
that low plasma levels of L-selectin reflect ongoing leukocyte
activation in patients with CAD.
Barath et al. (54) and Kaartinen et al. (55) localized
TNF-alpha in human atherosclerotic tissues, not only in mac-
rophages and mast cells, but also in the cytoplasm of and
attached to the cell membrane of smooth muscle cells and
endothelial cells. In the study by Vaddi et al. (21), enhanced
secretion of TNF-alpha and IFN-gamma from mononuclear
cells of patients with CAD was demonstrated, with a similar
increase in release of these cytokines from cultured mononu-
clear cells of patients with stable or unstable angina. This study
demonstrated a three- to fourfold increase in superoxide
generation in neutrophils from patients with CAD (vs. control
subjects) and suggested that this phenomenon may be a result
of continuous stimulation of mononuclear cells by cytokines.
The cytokines TNF-alpha and INF-gamma activate endothelial
cells and cause expression of adhesion molecules, neovascular-
ization and hemorrhagic necrosis and promote thrombogenesis
(43). In classic pathologic studies in patients who died of acute
myocardial infarction, van der Wal et al. (56) found that
macrophages and T lymphocytes were the dominant cell types
at the immediate site of either rupture or superficial erosion in
each case. These sites were characterized by abundant expres-
sion of HLA-DR antigen on both inflammatory cells and
adjacent smooth muscle cells, suggesting an active inflamma-
tory reaction. Taken together, these observations suggest
continuous ongoing inflammation in atherosclerosis, which
may play a role in the evolution of uncomplicated atheroma-
tous plaque into a complex atheroma. Repeated episodes of
ischemia may further enhance the inflammatory process in the
blood vessels and myocardial tissues. Acute exacerbation of
inflammation may have a role in destabilizing the fibrous cap
and enhance the risk of thrombosis.
Two recent clinical studies on the role of inflammation in
CAD are particularly noteworthy. Liuzzo et al. (57) reported
that the acute phase reactant, C-reactive protein, and serum
amyloid A protein were elevated in most patients with unstable
angina and recent acute myocardial infarction. Elevated levels
of these acute phase reactants at the time of hospital admission
were predictors of a poor outcome in patients with unstable
angina, and according to the authors, inflammation may be an
important component of acute myocardial ischemia. Ridker et
al. (58) recently reported on the plasma C-reactive protein
levels in participants of the Physicians’ Health Study and found
that the level of C-reactive protein was an independent signif-
icant predictive value in future myocardial infarction and
ischemic stroke. Importantly, the use of aspirin was associated
with marked reduction in the risk of myocardial infarction in
men in the highest quartile, but with a small insignificant
reduction in the lowest quartile. These authors suggested that
the anti-inflammatory action may be an important mechanism
of the beneficial effect of aspirin.
These observations taken together suggest the possibility
that atherosclerosis is a chronic inflammatory disease (22) that
develops in response to some metabolic, physical, infectious
and environmental process. T cells in the atherosclerotic
plaque express late-activation antigens and may also be active
participants in an active inflammatory response.
Thus, a stage has been set to examine the concept that
inflammation and atherosclerosis are closely associated, and
that acute ischemic events reflect exacerbation of a chronic
inflammatory state. Furthermore, acute myocardial injury as a
result of coronary thrombosis and reperfusion may be associ-
ated with more inflammation. Clearly inflammation begets
more inflammation.
HLA and Atherosclerosis
The HLA class I and class II molecules are cell surface
proteins that are essential for defense against infectious organ-
isms. The class I cell surface antigens are found on almost all
nucleated cells, and their function is to present intracellular
antigens from virus-infected or malignant cells to cytotoxic T
cells. The class II antigens present extracellular antigens from
bacteria or parasites to T-helper cells, and their expression is
restricted to macrophages and B-lymphocytes. Allelic variation
at the HLA genes can influence the ability to bind specific
antigens, as well as the interaction with a particular T-cell
receptor, by the presence of binding pockets specific to each
allele (59–61). Also, the stability of the D-dimer of the class II
molecule may be changed by allelic polymorphism.
The loci encoding the HLA antigens are among the most
polymorphic protein coding genes found in humans, with .180
alleles at the class I loci and .230 alleles at the class II loci. An
important practical consequence of the HLA polymorphism is
the rejection of transplanted organs, occurring when the HLA
matching between the donor and the recipient is not complete.
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Apart from being important in transplantation medicine, the
HLA antigen confers susceptibility to many diseases. No other
genomic region has been found to be associated with an
equivalent number of diseases, most of them with autoimmune
features, as the HLA region. Studies by Dahlen et al. (14,15)
have shown an association of certain inherited HLA-DR class
II genotypes with atherosclerosis and diabetes.
Role of Infection in Pathogenesis of
Atherosclerosis
It is well known that the traditional risk factors, such as
hypercholesterolemia, smoking, hypertension and diabetes, do
not explain atherosclerosis in a significant number of patients.
Particularly, the high prevalence of CAD in developing coun-
tries is associated with a relatively low frequency of smoking
and normal or low total cholesterol levels (62). Notably, the
decline in CAD-related mortality in the United States began
before the awareness of traditional risk factors and the em-
phasis on their control. The development of novel therapeutic
strategies over the past 10 years (e.g., thrombolytic therapy,
cholesterol-lowering drugs, antiplatelet drugs and antithrom-
bins and catheter-based coronary interventions) also cannot
explain the gradual and steady decline of CAD-related mor-
tality during the past 25 years. The decrease in CAD-related
mortality has been much smaller in Europe despite control of
risk factors and the use of therapeutic strategies similar to
those in the United States. During the same 20- to 25-year
period, there appears to be a marked increase in cases of CAD
and CAD-related mortality in Asia (2). These observations
also suggest the possibility that different etiologies may be
involved in atherogenesis in different populations.
An infectious etiology of atherosclerosis has received con-
siderable attention recently (23). This theory was initially
formulated in the first two decades of this century (63,64), but
did not receive much attention until the late 1970s when
Fabricant et al. (65) showed that chickens infected with avian
herpesvirus developed vascular lesions similar to those found
in human atherosclerosis. Since then a number of infectious
agents have been implicated in human atherosclerosis and
include Chlamydia pneumoniae, Helicobacter pylori, herpes
simplex virus and cytomegalovirus (CMV) (66–70), on the
basis of finding these infectious agents in the atherosclerotic
segments and by positive serology.
Chlamydia pneumoniae and atherosclerosis. Laboratory ev-
idence. Chlamydia pneumoniae is a species of Chlamydia that
causes pneumonia, bronchitis, pharyngitis and sinusitis. It is
distinguished from Chlamydia trachomatis and Chlamydia psittaci
on the basis of DNA sequence and electron microscopic
morphology of the elementary body. It has been found to have
only one immunotype, named TWAR, from the laboratory
designation of the first two isolates (TW-183 and AR-39). Now
the term TWAR is used synonymously with C. pneumoniae.
Gaydos et al. (71) and Wyrick and Brunridge (72) have
demonstrated that C. pneumoniae can replicate and maintain
infection in human macrophages, endothelial cells and aortic
smooth muscle cells. These cell types show particular suscep-
tibility to infection with C. pneumoniae (73). Fryer et al. (74)
have shown that C. pneumoniae can infect cultured human
vascular endothelial cells and stimulate a fourfold increase in
the expression of tissue factor and platelet adhesion, thus
providing a link between infection with C. pneumoniae and
procoagulant activity. Moazed et al. (75) have examined the
relation of infection with C. pneumoniae with atherosclerosis in
two different animal models: apolipoprotein E-deficient trans-
genic mice, which spontaneously develop atherosclerosis, and
C57BL/6J mice, which only develop atherosclerosis on an
atherogenic diet. After intranasal inoculation in these animal
models, Chlamydia pneumoniae was persistently detected in
atherosclerotic regions of the aorta by polymerase chain reaction
(PCR) and immunocytochemistry. Serum antibody levels (elevat-
ed IgG titers) were also positive for up to 12 weeks.
Clinical evidence. The association of C. pneumoniae infec-
tion with human atherosclerosis comes from several observa-
tions. IgG antibodies to C. pneumoniae are uncommon among
children and increase in early adulthood until the prevalence
reaches 70% in men and 50% in women (76). The prevalence
of positive serologic evidence is ;25% higher in men than in
women (77), which is consistent with the higher prevalence of
atherosclerosis in men than in women. Saikku et al. (78)
provided the first serologic evidence of an association of C.
pneumoniae with CAD in 1988. They examined serum samples
from 40 male patients with acute myocardial infarction, 30
male patients with chronic CAD and 41 control subjects and
found that 68% of patients with acute myocardial infarction
and 50% of patients with chronic CAD had elevated IgG
($1/128) or IgA ($1/32) titers, or both against C. pneumoniae.
In contrast, only 17% of control subjects had high titers. Since
the initial report by this Finnish group, several studies have
demonstrated this association in a variety of patients with CAD
using seroepidemiologic evidence (15). It is noteworthy that
Spodick et al. (79) in 1984 suggested the association of acute
respiratory symptoms with the onset of acute myocardial
infarction in a prospective investigation of 150 consecutive
patients and matched control subjects.
The presence of the C. pneumoniae organism has been
demonstrated in the atherosclerotic plaque itself using a
variety of techniques, such as PCR, electron microscopy,
immunostaining and culture of the organism (69,77,80–83). In
1992 Shor et al. (80) detected C. pneumoniae in fatty streaks
and atheromatous lesions in seven autopsy cases. TWAR-like
organisms were found in the lipid-rich core of fibrolipid
plaques and intimal smooth muscle cells. In five of seven cases,
immunoperoxidase staining was positive for C. pneumoniae.
There are now several reports on the presence of C. pneu-
moniae in atherosclerotic plaques from coronary arteries,
carotid arteries and the thoracic and abdominal aorta. Kuo et
al. (69) and Campbell et al. (77) reported finding C. pneu-
moniae in the coronary arteries of young adults (15 to 34 years
old) with atherosclerosis. Ong et al. (81) have recently re-
ported the presence of C. pneumoniae by PCR and immuno-
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staining in 44% of aortas, 55% of iliac arteries and 40% of
femoral arteries of patients with atherosclerosis.
Muhlestein et al. (82) recently reported immunofluores-
cence positivity for C. pneumoniae in 79% of 24 coronary
atherectomy coronary artery specimens. The presence of C.
pneumoniae was not related to conventional CAD risk factors,
the extent and severity of CAD or the clinical status of the
patients. Not all studies have shown a positivity for C. pneu-
moniae in atherosclerotic tissues; for example, Weiss et al. (84)
examined 79 coronary atherectomy specimens for C. pneu-
moniae by PCR or electron microscopy and found only one
PCR-positive specimen; all remaining 78 specimens were
negative.
We recently examined the association of Chlamydia with
coronary atherosclerosis in 60 autopsy specimens. Eighteen
cases had mild and 42 cases severe atherosclerosis. Of 42 cases
with severe atherosclerosis, 36 were immunopositive compared
with 1 of the 18 with mild atherosclerosis (p , 0.001). Lp(a)
levels were 190 6 44 mg/liter in cases with severe atheroscle-
rosis and 61 6 12 mg/liter in cases with mild atherosclerosis
(p , 0.0005). In addition, we found that 48% of cases with
severe atherosclerosis were positive for HLA-class II geno-
types 13 or 17 in cardiac muscle compared with 19% of cases
with mild atherosclerosis (p , 0.05). The study showed a
correlation between severe coronary atherosclerosis and Chla-
mydia in coronary arteries, high Lp(a) levels and certain
HLA-DR genotypes. These results are in favor of the hypothesis
that coronary atherosclerosis has a genetic and autoimmune
component and may be initiated by an intracellular infection (83).
Dahlen et al. (15) found serologic evidence (IgG titers $32)
for C. pneumoniae infection in 93% of patients with CAD and
78% of control subjects (p , 0.03). However, an IgG titer
$1/256 in combination with Lp(a) levels $120 mg/liter in-
creased the predictability of CAD (p , 0.01) in male patients.
Certain HLA-DR class II genotypes in combination with high
Lp(a) levels and C. pneumoniae titers were present in 14 (48%)
of 29 male patients with CAD compared with 1 (4%) of 27
male control subjects (p , 0.0005). This study, like ours,
showed an important interaction between infection and certain
inherited HLA class II genotypes.
The role of C. pneumoniae in carotid atherosclerosis has
also been evaluated in carotid endarterectomy specimens in
the Atherosclerosis Risk in Communities (ARIC) (70) study by
immunocytochemistry and PCR. All five fresh specimens and
32 of 56 archival formalin-embedded endarterectomy tissues
were positive for C. pneumoniae.
Herpes simplex virus, cytomegalovirus and atherosclerosis.
Human endothelial cells infected with herpesvirus demon-
strate thrombin formation and increased adherence of plate-
lets (85) and granulocytes (86). These observations provide
support for the initial observation of Fabricant et al. (65) that
chickens infected with herpesvirus developed vascular lesions
similar to those found in human atherosclerosis. Span et al.
(86) have studied cultured endothelial cells infected with CMV
and shown an increased adherence of leukocytes and platelets
to these cells. CMV induces major histocompatibility class I
antigen expression in human aortic smooth muscle cells (87).
Transfection with this virus also causes expression of genes for
several cytokines (e.g., IL-6) (88).
CMV DNA has been observed in the arterial walls of
patients with CAD (89,90). Infection with this virus has been
postulated to be a major risk factor for the rapid development
of vasculopathy or transplant atherosclerosis in patients who
underwent heart transplantation (91).
Epidemiologic studies (92) have shown that antibodies
against CMV are elevated in patients with CAD compared
with control subjects.
In a long-term prospective evaluation of a population-based
cohort, the ARIC study (70) found a significant correlation
between CMV infection and carotid-intimal-medial thickness.
The strongest association with CMV infection was that there
was a graded relation between the odds of intimal-medial
thickening and serum CMV antibody titer that remained
significant even after adjustment for conventional risk factors
for atherosclerosis.
Which pathogen is associated with atherosclerosis? Thus far,
the strongest association of atherosclerosis appears to be with
C. pneumoniae. The most significant association in most stud-
ies appears to be in coronary atherosclerosis. The organism has
been found in mature atherosclerosis and in early lesions. An
important association has been seen in whites and in temperate
latitudes. The overall association between C. pneumoniae and
coronary atherosclerosis using immunocytochemistry and di-
rect staining techniques appears to be about 70% to 100%. The
immunopositivity for C. pneumoniae is more prevalent in areas
of severe than mild coronary atherosclerosis (83), which raises
the possibility of severe or sustained infection or localization
and immobilization of the organism leading to severe athero-
sclerosis. There appears to be a relatively low association of
PCR positivity for C. pneumoniae with the severity or presence
of atherosclerosis. The discrepancy between the PCR and
immunostaining methods for the presence of C. pneumoniae
may relate to the extremely high sensitivity of the PCR
methodology. Actually, in our studies on coronary artery
specimens, PCR positivity in nonatherosclerotic and minimally
atherosclerotic regions was quite high.
Link Among Infection, Inflammation,
Thrombosis and Atherosclerosis
Chlamydia organisms, as well as CMV, induce production
of several cytokines, including TNF-alpha, IL-1 and IL-2
(88–93). These cytokines have a variety of actions, including
stimulation of fibroblasts and smooth muscle cell proliferation.
TNF-alpha inhibits the action of lipoprotein lipase (94), lead-
ing to altered lipid metabolism, accumulation of serum triglyc-
erides and a decrease in serum high density lipoprotein
cholesterol (HDL-C). Lipopolysaccharide, a bacterial compo-
nent, binds in human serum to both HDL-C and low density
lipoprotein cholesterol (LDL-C) (95) and makes LDL-C im-
munogenic or toxic to endothelial cells.
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Cytokines are potent inducers of a neutrophil free radical
generation, which may facilitate oxidation of LDL-C, a key
event in atherogenesis (9), and attract monocytes and other
inflammatory cells to the area of endothelial injury. Coupled
with the fibroblast and smooth muscle cell proliferating effects,
leukocyte activation may lead to propagation of the athero-
sclerotic process (16).
Free radicals also stimulate platelet activation and leuko-
cyte chemotaxis and may participate in the formation of
thrombus in atherosclerotically narrowed arteries. Cytokines
also influence the coagulation cascade by stimulating forma-
tion of endogenous tissue plasminogen activator and its fast-
acting inhibitor, plasminogen activator inhibitor-1, the overall
effect being stimulation of thrombus formation (43). Plasma
levels of both tissue-type plasminogen activator and plasmin-
ogen activator inhibitor-1 have been shown to be increased in
unstable coronary syndromes (10). Cytokines decrease the
activity of constitutive nitric oxide synthase (96), a hallmark of
atherosclerosis (24), and the loss of release of constitutive
nitric oxide may predispose to vasospasm and in situ platelet
aggregation and thrombosis.
Bacterial lipopolysaccharide is a potent stimulus for induc-
ible nitric oxide synthase activity (24) leading to the formation
of large amounts of nitric oxide, which could cause endothelial
dysfunction and disruption followed by deposition of mono-
cytes and platelets on the vessel wall, release of growth factors
and migration of smooth muscle cells.
Other well known risk factors, such as smoking, hyperten-
sion, homocyteinemia and altered fatty acid pool, may play a
variable, but important, role in the development of atheroscle-
rosis in susceptible people and precipitation of an acute
ischemic event. It is possible to develop a postulate wherein
infection and inflammation play a very important role in
atherogenesis in some subjects (Fig. 1).
Figure 1. Postulated steps in the pathogenesis of atherosclerosis. In
this postulate, infection and inflammation play an important role early
in the initiation of endothelial injury. The dysfunctional endothelium
permits monocyte deposition and infiltration of lipid-laden macro-
phages into the subendothelial layers. This is associated with a
decrease in constitutive nitric oxide (NO) formation and activity. NO
may be rapidly broken down by release of large amounts of free
radicals, resulting in focal vasospasm. Dyslipidemia, altered folate
metabolism (and resultant increased homocysteine levels) and growth
factor release cause smooth muscle cell (SMC) proliferation. Deposi-
tion and activation of inflammatory cells lead to release of procoagu-
lant cytokines and thrombosis. Increased release of free radicals and a
relative deficiency of endogenous antioxidant pool may oxidize lipids,
inactivate NO and enhance thrombosis and prevent thrombolysis. In
this postulate, abnormalities in lipid profiles, folate metabolism and
other traditional risk factors (e.g., diabetes mellitus and hypertension)
play a rather peripheral role and serve to amplify the atherosclerotic
process initiated by persistence of infection and inflammation. This
postulate is not designed to be operative in all patients with athero-
sclerosis, but only in those with genetic predisposition. Major abnor-
malities are listed in block letters. PMNs 5 polymorphonuclear
leukocytes.
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Potential of Antibiotic Therapy in
Atherosclerosis and CAD
Naturally if infection plays an important role in the patho-
genesis of chronic CAD and its acute exacerbation, therapy
with antibiotics may be a logical choice. Until recently, such
therapy would have been inconceivable. On the basis of the
laboratory and clinical evidence of C. pneumoniae infection in
coronary arteries, a small trial with azithromycin was carried
out in survivors of acute myocardial infarction in the United
Kingdom (97). Among 213 patients with a history of recent
myocardial infarction, 59 had undetectable IgG titers against
C. pneumoniae, 74 had intermediate range titers (between 8
and 32) and 80 had high (.1/64) titers. Patients with high titers
were randomized in a double-blind fashion to receive placebo
(n 5 20) or azithromycin 500 mg daily for 3 days (n 5 28) or
azithromycin 500 mg daily for 6 days (n 5 12). The primary
endpoints (cardiovascular death, hospital admission with un-
stable angina or acute myocardial infarction or need for
revascularization) at a mean follow-up period of 18 months
were observed in 7% of patients with undetectable initial IgG
titers, 15% of patients with intermediate levels and 28% of
patients with high IgG titers. Interestingly, the primary end-
points occurred in 8% of patients with high IgG titers who
were treated with azithromycin. This dramatic reduction in
endpoints in a small number of high risk patients with CAD
suggests the potential of antibiotic therapy in preventing acute
cardiac events.
Therapy with other antibiotic agents with greater activity
toward C. pneumoniae is in the planning phases.
Conclusions
Atherosclerosis is a multifaceted disease process with sev-
eral different well defined risk factors. It is unlikely that a
common pathway or pathogenic process can explain this
malady, which affects one-third of the world population. We
propose that in some genetically susceptible people or popu-
lations, a primary or repeated episodes of infection with a
common organism (e.g., C. pneumoniae or CMV) may result in
localization of the organism in arteries that are prone to
hemodynamic stress. A deficiency of endogenous protective
mechanisms or immune response may prompt persistent
growth of the organism in situ and a state of inflammation,
platelet activation, vasospasm and thrombosis may ensue.
Oxidation of LDL-C and alterations in lipid metabolism may
participate secondarily in the process of inflammation. Acute
exacerbation of chronically inflamed atherosclerotic tissues
may be the basis of rupture of plaque or plaque thrombosis and
hemorrhage resulting in the clinical syndromes of unstable
angina and acute myocardial infarction. This scenario obvi-
ously is not meant or designed to explain atherosclerosis or its
manifestations in all people, but it may be quite relevant in
many patients. The infectious basis of atherosclerosis may
underlie the variable rates of prevalence of CAD in different
parts of the world and the rapidly changing patterns of
morbidity and mortality from CAD in the United States and
elsewhere, which cannot be explained by conventional risk
factors. Despite the reported link between atherosclerosis and
the presence of Chlamydia infection, the cause and effect
relation remains to be proved. We believe that large clinical
trials of therapy with antibiotics should be conducted to
determine whether C. pneumoniae plays a critical role in the
pathogenesis of atherosclerotic CAD. Meanwhile, large-scale
studies need to be done to examine individual susceptibility to
C. pneumoniae infection and its correlation with atherogenesis.
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